Literature DB >> 18620932

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

Vernon K Sondak1, Lawrence E Flaherty.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18620932     DOI： 10.1016/S0140-6736(08)61011-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Sentinel node biopsy needs for a suitable therapeutic management of the cutaneous melanoma.

Authors:  Ettore Minutilli; Uwe Trefzer; Eggert Stockfleth; Wolfram Sterry
Journal:  Nat Clin Pract Oncol       Date:  2009-01

Review 2.  Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.

Authors:  Yi-chi M Kong; Wei-Zen Wei; Yaron Tomer
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

3.  Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma.

Authors:  Ricardo J Gonzalez; Ragini Kudchadkar; Nikhil G Rao; Vernon K Sondak
Journal:  Ochsner J       Date:  2010

4.  Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.

Authors:  A I Daud; C Xu; W-J Hwu; P Urbas; S Andrews; N E Papadopoulos; L C Floren; A Yver; R C Deconti; V K Sondak
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-28       Impact factor: 3.333

5.  Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

Authors:  A Hauschild
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.